Polymer-encapsulated drug particles
AssigneeTonic Medical, Inc.
InventorsLixiao Wang, Peter Barnett
Life of this patent
Estimating the term…
Abstract
Various embodiments disclosed relate to polymer-encapsulated drug particles and a drug-releasing coating including the same, as well as drug-coated balloon catheters for treating, preventing, or reducing the recurrence of strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes the polymer-encapsulated drug particles; or a drug-releasing coating including the polymer-encapsulated drug particles; or a therapeutic agent and a first and/or second additive; or a combination thereof.
Claims30
A drug-releasing coating comprising:
- polymer-encapsulated drug particles comprising
- a therapeutic agent;
- one or more polymers that encapsulate the therapeutic agent;
- and
- a first ionic or zwitterionic additive in the polymer-encapsulated drug particles;
- wherein the first ionic or zwitterionic additive comprises 1,2-dihexanoyl-sn-glycero-3-phosphocholine, 1,2-diheptanoyl-sn-glycero-3-phosphocholine, 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dinonanoyl-sn-glycero-3-phosphocholine, 1,2-didecanoyl-sn-glycero-3-phosphocholine, 1,2-diundecanoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), or a combination thereof;
- and
- a release matrix comprising a second ionic or zwitterionic additive, wherein the second ionic or zwitterionic additive comprises a mismatched charged lipid and/or phospholipid, wherein two acyl groups of the mismatched charged lipid or phospholipid comprise mis-matched acyl groups, and wherein the mis-matched acyl groups differ by length, degree of saturation, substituents thereon, substitution patterns thereon, or combinations thereof, wherein the release matrix comprises the polymer-encapsulated drug particles dispersed therein.
Dependencies are inferred from the claim text.